Bright Minds: BMB-101 Takes Center Stage Ahead Of Phase 3 Pivotal Trials (NASDAQ:DRUG)
· seekingalpha.com
Bright Minds Biosciences (DRUG) stock analysis: Hold rating on dilution risk, BMB-101 Phase 3 uncertainty, and ~48% overvaluation.
Bright Minds Biosciences Inc. ( DRUG ) is a pre-revenue company that has a targeted platform approach. What this means is that one drug (next-generation seroton...